SpringWorks Therapeutics, Inc.

NasdaqGS:SWTX

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

Location

United States

Market Cap

USD 3.54 B

Share Price

USD 46.98

Avg Daily Volume

4,950,914

Change (1 day)

-0.02%

Change (1 year)

25.18%

Change (YTD)

30.03%

SpringWorks Therapeutics, Inc. Share Price on June 27, 2025: USD 46.98

SpringWorks Therapeutics, Inc. Share Price is USD 46.98 on June 27, 2025, a 25.18% change year over year. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance.

SpringWorks Therapeutics, Inc. 52-week low Share Price is USD 59.93 on June 27, 2025, which is 27.56% above the current Share Price.
SpringWorks Therapeutics, Inc. 52-week low Share Price is USD 28.61 on June 27, 2025, which is -39.10% below the current Share Price.
SpringWorks Therapeutics, Inc. average Share Price for the last 52 weeks is USD 40.56.

Daily

From:

To:

Zoom:

Key data

Date	Share Price	Share Price	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)

NasdaqGS: SWTX

SpringWorks Therapeutics, Inc.

CEO	Mr. Saqib Islam J.D.
IPO Date	Sept. 13, 2019
Location	United States
Headquarters	100 Washington Boulevard
Employees	368
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology

Description

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.